Gynecologic cancers (including endometrial, ovarian, cervical, etc.) represent one of the most common causes of mortality in women. This phenomenon is related to the absence, except in the case of cervical cancer, of valid screening methodologies. Current treatment strategies for advanced stage patients include chemotherapy and radiation; however, as for other malignancies, several advances have been made in the field of targeted therapies. Therefore, the assessment of specific biomarkers to elect patients for targeted therapies is crucial.
Accurate molecular assessment of clinically relevant and validated biomarkers is crucial in adminstering the best treatment for advanced stage gynecological cancer patients. In this setting, molecular predictive pathology has acquired a key role in the management of these patients. The efficacy of Poly (ADP-ribose) Polymerase (PARP) inhibitors (PARPi) in patients harboring genomic alterations in breast cancer (BRCA) 1 and 2 genes has already been widely demonstrated and careful attention has been paid to the role of immune-checkpoint inhibitors (ICIs) in patients harboring a high microsatellite instability (MSI-H) status.
In this Research Topic we would like to discuss the methods, findings and prospects of evidence from molecular pathology that will help in the early diagnosis, treatment decision-making and drug resistance prediction in gynecological malignancies. Articles of the Original Research, Review, Mini Review, Opinion and Perspective type will be considered. Potential topics include but are not limited to the following:
1) The role of different BRCA alterations as predictors of response to PARPi;
2) Validated biomarkers associated with immunotherapy outcomes;
3) Validated biomarkers for prediction of drug resistance;
4) Next-generation sequencing and its application in the diagnosis of gynecological malignancies;
5) The role of HRD.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Umberto Malapelle has received personal fees (as consultant and/or speaker bureau) from Boehringer Ingelheim, Roche, MSD, Amgen, Thermo Fisher Scientifics, Eli Lilly, Diaceutics, GSK, Merck and AstraZeneca.
Gynecologic cancers (including endometrial, ovarian, cervical, etc.) represent one of the most common causes of mortality in women. This phenomenon is related to the absence, except in the case of cervical cancer, of valid screening methodologies. Current treatment strategies for advanced stage patients include chemotherapy and radiation; however, as for other malignancies, several advances have been made in the field of targeted therapies. Therefore, the assessment of specific biomarkers to elect patients for targeted therapies is crucial.
Accurate molecular assessment of clinically relevant and validated biomarkers is crucial in adminstering the best treatment for advanced stage gynecological cancer patients. In this setting, molecular predictive pathology has acquired a key role in the management of these patients. The efficacy of Poly (ADP-ribose) Polymerase (PARP) inhibitors (PARPi) in patients harboring genomic alterations in breast cancer (BRCA) 1 and 2 genes has already been widely demonstrated and careful attention has been paid to the role of immune-checkpoint inhibitors (ICIs) in patients harboring a high microsatellite instability (MSI-H) status.
In this Research Topic we would like to discuss the methods, findings and prospects of evidence from molecular pathology that will help in the early diagnosis, treatment decision-making and drug resistance prediction in gynecological malignancies. Articles of the Original Research, Review, Mini Review, Opinion and Perspective type will be considered. Potential topics include but are not limited to the following:
1) The role of different BRCA alterations as predictors of response to PARPi;
2) Validated biomarkers associated with immunotherapy outcomes;
3) Validated biomarkers for prediction of drug resistance;
4) Next-generation sequencing and its application in the diagnosis of gynecological malignancies;
5) The role of HRD.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Umberto Malapelle has received personal fees (as consultant and/or speaker bureau) from Boehringer Ingelheim, Roche, MSD, Amgen, Thermo Fisher Scientifics, Eli Lilly, Diaceutics, GSK, Merck and AstraZeneca.
